Analysts Anticipate Adamas Pharmaceuticals, Inc. (ADMS) to Announce -$1.06 EPS
Equities research analysts expect Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings of ($1.06) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Adamas Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.00) and the lowest estimate coming in at ($1.17). Adamas Pharmaceuticals posted earnings per share of ($0.66) during the same quarter last year, which would suggest a negative year-over-year growth rate of 60.6%. The company is scheduled to issue its next quarterly earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full year earnings of ($3.88) per share for the current financial year, with EPS estimates ranging from ($4.07) to ($3.77). For the next year, analysts anticipate that the firm will report earnings of ($2.19) per share, with EPS estimates ranging from ($2.79) to ($1.26). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by $0.12. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter in the previous year, the business earned ($0.78) EPS. The business’s revenue for the quarter was down 90.9% on a year-over-year basis.
A number of equities research analysts have weighed in on ADMS shares. BidaskClub upgraded Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 23rd. Zacks Investment Research downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd. Noble Financial restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, August 9th. Cowen and Company restated an “outperform” rating and issued a $45.00 target price on shares of Adamas Pharmaceuticals in a research report on Sunday, May 28th. Finally, JMP Securities restated an “outperform” rating and issued a $33.00 target price (up from $29.00) on shares of Adamas Pharmaceuticals in a research report on Friday. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $32.50.
ILLEGAL ACTIVITY NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/analysts-anticipate-adamas-pharmaceuticals-inc-adms-to-announce-1-06-eps/1529315.html.
Shares of Adamas Pharmaceuticals (ADMS) opened at 20.27 on Tuesday. The firm has a 50-day moving average price of $16.54 and a 200-day moving average price of $16.78. Adamas Pharmaceuticals has a 1-year low of $12.10 and a 1-year high of $21.44. The stock’s market cap is $456.36 million.
In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of the company’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $17.05, for a total value of $5,967,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 731,041 shares of company stock valued at $12,476,149 over the last 90 days. 29.00% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Adamas Pharmaceuticals by 4.0% in the second quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock valued at $13,034,000 after buying an additional 28,818 shares in the last quarter. Alliancebernstein L.P. boosted its position in Adamas Pharmaceuticals by 2.6% in the second quarter. Alliancebernstein L.P. now owns 717,617 shares of the specialty pharmaceutical company’s stock valued at $12,551,000 after buying an additional 17,972 shares in the last quarter. Emerald Advisers Inc. PA boosted its position in Adamas Pharmaceuticals by 2.7% in the second quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock valued at $9,317,000 after buying an additional 14,042 shares in the last quarter. State Street Corp boosted its position in Adamas Pharmaceuticals by 9.1% in the second quarter. State Street Corp now owns 285,359 shares of the specialty pharmaceutical company’s stock valued at $4,990,000 after buying an additional 23,708 shares in the last quarter. Finally, Granite Point Capital Management L.P. boosted its position in Adamas Pharmaceuticals by 11.9% in the second quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock valued at $4,609,000 after buying an additional 28,000 shares in the last quarter. 69.24% of the stock is currently owned by institutional investors.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.